BERDAZIMER SODIUM generics — when can they launch?
BERDAZIMER SODIUM (BERDAZIMER SODIUM) · · 14 active US patents · 0 expired
Where BERDAZIMER SODIUM sits in the generic timeline
All listed Orange Book patents for BERDAZIMER SODIUM have expired. Generic entry is permitted, and ANDA filers can launch without patent infringement risk. Hatch-Waxman exclusivity (NCE/ODE/PED) may still apply if recently approved.
Under US Hatch-Waxman, a generic enters via an ANDA (Abbreviated New Drug Application) and may file with one of four Paragraph IV certifications attacking the brand's listed patents. If the brand sues within 45 days, a 30-month FDA approval stay is triggered. First Para IV filer typically gets 180-day market exclusivity.
Patent estate by type — active patents
Method-of-use patents only carve out specific indications; generics can launch with a "skinny label" omitting those uses. Composition-of-matter patents block the molecule itself.
- Method of Use — 8 patents
- Formulation — 4 patents
- Composition of Matter — 2 patents
FDA U-codes carved out by BERDAZIMER SODIUM patents
Method-of-use patents are listed against specific FDA Patent Use Codes ("U-codes") representing carved-out indications. Generics can launch with a label that omits these uses.
| U-code | Description |
|---|---|
U-3802 | (no description) |
U-3803 | (no description) |
U-3800 | (no description) |
U-3797 | (no description) |
U-3793 | (no description) |
U-3789 | (no description) |
U-3790 | (no description) |
U-3788 | (no description) |
Sample patent estate
Showing 6 of 14 active US patents. View full estate on the BERDAZIMER SODIUM drug page →
-
This patent protects the composition of matter of nitric oxide-releasing particles for delivering nitric oxide in biomedical and pharmaceutical applications.USPTO title: Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications
-
This patent protects the composition of matter of nitric oxide-releasing particles for delivering nitric oxide in biomedical and pharmaceutical applications.USPTO title: Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications
-
This patent protects topical gels that release nitric oxide and methods of using them to treat wounds and other skin ailments.USPTO title: Topical gels and methods of using the same
-
This patent protects topical gels that release nitric oxide and methods of using them to treat wounds and other skin ailments.USPTO title: Topical gels and methods of using the same
-
This patent protects topical gels that comprise diazeniutndiolate-functionalized polysiloxane macromolecules and methods of using them to treat wounds and other skin ailments.USPTO title: Topical gels and methods of using the same
-
USPTO title: Anhydrous compositions
Sources
- FDA Orange Book — patents listed against BERDAZIMER SODIUM (NDA filed 2024)
- BERDAZIMER SODIUM drug profile — full patent estate, indications, clinical trials, pricing
- Patent cliff 2026 — every drug losing US exclusivity that year
Patent term extensions (PTR, pediatric exclusivity), Hatch-Waxman 30-month stays, and FDA regulatory exclusivity (NCE/ODE/PED) may shift the effective generic entry date. Not legal advice.
Get generic entry alerts
Free Pharma CI alerts on BERDAZIMER SODIUM — get notified the moment an ANDA Paragraph IV certification is filed, a 30-month stay is triggered, or a generic launches. First 2 drugs free.
Subscribe free →